10.4067/S0718-95162015005000019 68 HernndezI.ChacnO.RodriguezR.PortielesR.LpezY.PujolM.et al
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
1,067.00Current price is: 1,067.00
Larger metabolite panels also improve the understanding of biological complexity, revealing novel associations and fluxes between biochemical pathways [60]
No dosage adjustment is needed for patients with renal impairment, though renal function should be monitored in patients experiencing severe adverse gastrointestinal reactions
100023.DOI
